“…Brøsen et al randomized 149 persons with T1D who had had ≥1 severe nocturnal hypoglycemia episode during the prior 2 years to insulin degludec versus insulin glargine U100, finding coefficient of variation of continuous glucose monitoring during the night significantly lower at 35.7% versus 39.6%, with significantly lower time below 54 mg/dl at 1.8% versus 3.1%. 38 Bergenstal et al reported a 12‐week open‐label trial of 343 T1D persons randomized to insulin glargine 300 U/ml and degludec 100 U/ml showing similar within‐day and between‐day glucose coefficient of variation, suggesting comparable clinical benefit of these two insulin preparations. 39 Mathiesen et al 40 compared 1434 women with T1D during pregnancy receiving insulin aspart versus 406 receiving other bolus insulin preparations, showing significantly lower third trimester HbA1c of 6.59% versus 6.75%, but with similar propensity‐score matched likelihood of severe hypoglycemia, abortion, preterm delivery, preeclampsia, birthweight large for gestational age, and major congenital malformations.…”